The GLP-1 receptor agonist exendin-4 increased the firing rate of dopamine-producing neurons in the substantia nigra in both normal and parkinsonian mice, with endogenous GLP-1 also contributing to this excitatory effect through PKA and TRPC4/5 channels.
Excitatory effect preserved in PDBoth exogenous and endogenous GLP-1 maintained their ability to stimulate surviving dopamine neurons in a parkinsonian state
What the researchers found
Exendin-4 (GLP-1R agonist) significantly increased the spontaneous firing rate and decreased firing regularity of nigral dopaminergic neurons in normal C57BL/6 mice. Blocking GLP-1 receptors with exendin(9-39) decreased firing rate, confirming that endogenous GLP-1 tonically modulates these neurons.
The excitatory effect involved PKA signaling and TRPC4/5 (transient receptor potential canonical) ion channels. Critically, both exogenous and endogenous GLP-1 maintained their excitatory effects on surviving dopaminergic neurons in a parkinsonian state. Since mild excitatory stimulation promotes neuroprotection and TH expression in dopamine neurons, the GLP-1-mediated excitation may partially contribute to anti-parkinsonian effects.
Why it matters
GLP-1 receptor agonists are already in clinical trials for Parkinson's disease based on epidemiological and early clinical evidence. This study provides a specific neurophysiological mechanism: GLP-1 directly excites the very neurons that are dying in Parkinson's. This is important because understanding why GLP-1 drugs might protect dopamine neurons helps optimize treatment strategies and supports the rationale for larger clinical trials of peptide-based neuroprotection in Parkinson's disease.
How the study worked
In vivo extracellular single-unit electrophysiological recordings were performed in the substantia nigra pars compacta of adult male C57BL/6 mice (both normal and parkinsonian models). Exendin-4 was applied as a GLP-1R agonist, and exendin(9-39) as a GLP-1R antagonist. Downstream signaling pathways were investigated using PKA inhibitors and TRPC4/5 channel blockers. Spontaneous firing rate and firing regularity of dopaminergic neurons were the primary outcomes.
What this study cannot tell us
This is an animal electrophysiology study in mice that may not directly predict effects in the human brain. The parkinsonian model may not fully replicate the complexity of human Parkinson's disease. Only acute GLP-1R activation was studied — chronic effects on neuron survival were not assessed. The neuroprotective conclusion is inferred from the excitatory effect but not directly demonstrated in this study. Specific mouse numbers per experimental condition are not reported in the abstract.
How to read the evidence
This is a well-designed in vivo electrophysiology study with pharmacological validation (agonist, antagonist, and pathway blockers). It provides strong mechanistic evidence for GLP-1 action on dopamine neurons but is limited to a mouse model with no clinical data.
When this study was published
Published in 2024, this study is current and directly supports ongoing clinical trials of GLP-1 agonists for Parkinson's disease, including the positive results from the exenatide phase 2 trial.
The bigger picture
This study adds to the rapidly growing evidence that GLP-1 peptides have important roles in the brain beyond appetite regulation. The finding that GLP-1 receptors on substantia nigra dopamine neurons are functionally active — and that their activation could be neuroprotective — provides mechanistic support for the clinical trials of exenatide and lixisenatide in Parkinson's disease. It also suggests that the brain's endogenous GLP-1 system may naturally contribute to dopamine neuron health, opening questions about whether impaired central GLP-1 signaling could contribute to Parkinson's pathogenesis.
Questions still open
- Does chronic GLP-1 receptor activation actually slow the death of dopamine neurons in Parkinson's models, or is the acute excitatory effect transient?
- Are GLP-1 receptor levels or endogenous GLP-1 production altered in the substantia nigra of Parkinson's disease patients?
- Could combining GLP-1 agonists with other neuroprotective strategies provide synergistic protection for dopamine neurons?
Common questions
Could diabetes drugs help treat Parkinson's disease?
How does GLP-1 protect brain cells?
Read the original research
GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
Neuropharmacology, 252, 109946
Citation
Liu, Cui; Liu, Wen-Hong; Yang, Wu; Chen, Lei; Xue, Yan; Chen, Xin-Yi. (2024). GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.. Neuropharmacology, 252, 109946. https://doi.org/10.1016/j.neuropharm.2024.109946